A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation
Latest Information Update: 24 Jul 2024
At a glance
- Drugs Zamtocabtagene autoleucel (Primary) ; Bendamustine; Gemcitabine; Oxaliplatin; Polatuzumab vedotin; Rituximab
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms DALY 2-EU
- Sponsors Miltenyi Biotec GmbH
- 19 Jul 2024 Status changed from recruiting to active, no longer recruiting.
- 26 Jan 2024 Planned End Date changed from 31 Dec 2024 to 31 Jul 2027.
- 26 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.